A weekly diabetes medication may replace painful daily hormone injections for patients with congenital generalised lipodystrophy (CGL). Early findings suggest that tirzepatide – used for diabetes and ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

More prescriptions were handed out for semaglutide – a drug used to treat diabetes – in east Berkshire, north east Hampshire, ...

The rationale for the study, according to the authors, is that “Nearly 2% of the US population received a prescription for ...

A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

More prescriptions were handed out for semaglutide – a drug used to treat diabetes – in Surrey Heartlands last year, figures show.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Eli Lilly plans to launch Mounjaro, an anti-diabetes and weight loss drug, in India by 2025. The medication, which is ...